Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in

Study met primary endpoint, significant improvement in radiographic progression-free survival. Overall Response Rate was 38.1% vs. 12.0% for ARPI switch arm, including 9.3% Complete Responses.